The US Food and Drug Administration (FDA) has given a green light to Merck's sotatercept-csrk, known by the brand name WINREVAIR, for the treatment of adults with pulmonary arterial hypertension ...

The Food and Drug Administration approved Winrevair as an add-on therapy to other drugs for pulmonary arterial hypertension, which is commonly known as PAH.

Winrevair’s approval comes a few days after the FDA approved Johnson & Johnson’s Opsynvi, a fixed-dose combination of endothelin antagonist macitentan and PDE-5 inhibitor tadalafil.

In March, Winrevair became the first FDA-approved therapy for PAH that addresses the underlying mechanism behind the disease, rather than its symptoms, and has also been cleared in Europe and ...

Winrevair is FDA-approved for the treatment of adults with pulmonary arterial hypertension (PAH, WHO Group 1) to increase exercise capacity, improve WHO functional class (FC) and reduce the risk of ...

Adding Winrevair to standard pulmonary arterial hypertension (PAH) treatment is generally safe and effective, a pooled trial ...

Winrevair was approved by the US Food and Drug Administration (FDA) in March 2024 following results from the STELLAR (NCT04576988) trial and has since been approved in 38 other countries.

For the first time in two decades, the Food and Drug Administration (FDA) has approved a new class of medication that provides an alternative to addictive opioids for patients looking to manage ...

Last March, the Food and Drug Administration (FDA) approved Winrevair, a treatment for adults with pulmonary arterial hypertension. Fourth-quarter Winrevair sales climbed to an annualized $800 ...